Graft-versus-host disease (GVHD) is a major complication of allogeneic bone
marrow transplantation. One strategy to treat GVHD is to equip donor T cel
ls with a conditional suicide mechanism that can be triggered when GVHD occ
urs. The herpes simplex virus thymidine kinase (HSV-tk)/ganciclovir system
used clinically has several limitations, Including immunogenicity and cell
cycle dependence. An alternative switch based on chemically inducible apopt
osis was designed and evaluated, A chimeric human protein was expressed com
prising an extracellular marker (Delta LNGFR), the Pas intracellular domain
, and 2 copies of an FK506-binding protein (FKBP), Primary human T lymphocy
tes retrovirally transduced with this construct could be purified to homoge
neity using immunomagnetic beads. Genetic integrity of the construct was en
sured by redesigning repetitive sequences. Transduced T cells behaved indis
tinguishably from untransduced cells, retaining the ability to mount a spec
ific; antiallogeneic immune response, However, they rapidly underwent apopt
osis with the addition of subnanomolar concentrations of AP1903, a bivalent
"dimerizer" drug that binds FKBP and induces Pas cross-linking, A single P
-hour treatment eliminated approximately 80% of T cells, and multiple expos
ures induced further apoptosis. T cells were eliminated regardless of their
proliferation state, suggesting that the AP1903/Fas system, which contains
only human components, is a promising alternative to HSV-fk for treating G
VHD, (Blood, 2001; 97:1249-1257) (C) 2001 by The American Society of Hemato
logy.